ProQR Therapeutics

Developing medicines using our proprietary Axiomer RNA-editing technology platform
$PRQR #RNA #biotech #Axiomer #RNAediting

[ProQR Therapeutics @ProQR]

#BiliaryAtresia (BA) is the leading cause of liver transplantation in children. This #LiverAwarenessMonth, we’re highlighting the urgent need for new options for patients and families affected by BA.

Learn more: https://t.co/vuEV6Lkad5

#RareDisease #RNAEditing #Axiomer

[ProQR Therapeutics @ProQR]

This #LiverAwarenessMonth, we’re raising awareness of #BiliaryAtresia (BA), a rare liver disease that affects newborns and young children.

For more information about BA, visit our website: https://t.co/G9UAeXDtOr

#RareDisease #PediatricLiverDisease #Axiomer #RNAEditing

[ProQR Therapeutics @ProQR]

Starting today at 11a ET. Join us for our virtual Investor & Analyst Educational Event on NTCP modulation in biliary atresia. Details and registration below.

[ProQR Therapeutics @ProQR]

On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.

For additional information about the event and to register, visit: https://t.co/Gnw4a05KyA

#Axiomer #RNAEditing @ProQR

[ProQR Therapeutics @ProQR]

On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.

For additional information about the event and to register, visit: https://t.co/Gnw4a05KyA

#Axiomer #RNAEditing @ProQR

[ProQR Therapeutics @ProQR]

On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.

For additional information about the event and to register, visit: https://t.co/Gnw4a05KyA

#Axiomer #RNAEditing @ProQR

[ProQR Therapeutics @ProQR]

Axiomer Insights: Our team published findings in Scientific Reports on preclinical liver models for ADAR-mediated RNA editing. Monica from our research team discusses how model selection can inform translatability for our #Axiomer #RNAEditing platform.

https://t.co/7zRw6rhdPc

[ProQR Therapeutics @ProQR]

To learn more, read the PR: https://t.co/XtcPWNLUqP

And check out the blog on our website: https://t.co/ZQYqBfsI9i

[ProQR Therapeutics @ProQR]

ProQR welcomes Chris Hart as Chief Data & AI Officer and Thomas Wolf as Strategic AI Advisor to the Board. Their appointments support our strategy to apply AI across discovery and development. AX-0811, the first AI-discovered ProQR program is now in clinical trials.

#Axiomer

[ProQR Therapeutics @ProQR]

Meet Anne Geert from our CMC team! He is responsible for producing the drug substances used in our preclinical and clinical programs. He also helps organize the ProQR conference.

Learn more: https://t.co/epAvphpvVj

#Axiomer #TeamProQR

[ProQR Therapeutics @ProQR]

Today we released our Q2 2026 financial results and provided a business update. Read the full press release on our website: https://t.co/4tiFlDM8Pg

$PRQR #Biotech #Axiomer #RNAEditing

[ProQR Therapeutics @ProQR]

ProQR has made available a video featuring it’s Management Team discussing the Phase 1 AX-0810 data, the clinical validation of the #Axiomer #RNAEditing platform, AX-0811 and next steps with NTCP.

Watch here: https://t.co/hBZ7Ieralt

[ProQR Therapeutics @ProQR]

Last week, ProQR co-founder Dinko Valerio joined the team to reflect on ProQR’s journey from an ambitious idea to advancing our #Axiomer #RNAEditing platform in the clinic.

We are grateful to Dinko for his contributions over the years and for sharing his passion and insights.

[ProQR Therapeutics @ProQR]

Today is #MPSAwarenessDay.

#Hurlersyndrome is a severe form of MPS and is associated with significant disease burden, impacting quality of life and life expectancy.

We recently announced AX-0422, a potential #RNAEditing therapy in development for Hurler syndrome.

#ShineforMPS

[ProQR Therapeutics @ProQR]

We’re excited to share that ProQR will present new data across multiple scientific conferences this May, highlighting the breadth of our Axiomer™ RNA editing platform.

For more details, check out the PR: https://t.co/L1JGEO9KHD

#RNAEditing #Biotech

[ProQR Therapeutics @ProQR]

Drug discovery can be slow and patients are waiting.

Our CEO Daniel de Boer and Ginkgo CEO Jason Kelly sat together to discuss how our collaboration is accelerating our #Axiomer #RNAEditing platform development.

#Biotech #AI

[ProQR Therapeutics @ProQR]

Following our partnership announcement with @Ginkgo Bioworks, our CEO Daniel de Boer sat down with Ginkgo CEO Jason Kelly to discuss the opportunity ahead.

Hear how our #Axiomer #RNAEditing platform, automation, and data can accelerate drug development.

#Biotech #AI

[ProQR Therapeutics @ProQR]

Today we highlighted key updates in our Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810.”

Check out the PR for more details: https://t.co/5jJunMotQg and watch the replay of the event: https://t.co/zYa1c3bhYx

#Axiomer #Biotech

[ProQR Therapeutics @ProQR]

In one hour, at 10:00 ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”.

For additional information about the event and to register, visit: https://t.co/f5Fqws4cYb

#Axiomer #RNAEditing

[ProQR Therapeutics @ProQR]

We’re excited to introduce our partnership with Ginkgo Bioworks and in addition our AI Advisory Board, helping to bring #Axiomer #RNAEditing therapies to patients faster.
Learn more at our Virtual Investor & Analyst event today at 10:00 ET: https://t.co/f5Fqws4cYb

[ProQR Therapeutics @ProQR]

On April 8th at 10:00 am ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”.

For additional information about the event and to register, visit: https://t.co/f5Fqws4cYb

#Axiomer #RNAEditing